Your browser doesn't support javascript.
loading
Contributions Of Public Health, Pharmaceuticals, And Other Medical Care To US Life Expectancy Changes, 1990-2015.
Buxbaum, Jason D; Chernew, Michael E; Fendrick, A Mark; Cutler, David M.
Afiliação
  • Buxbaum JD; Jason D. Buxbaum (jasonbuxbaum@g.harvard.edu) is a student in the Program in Health Policy at Harvard University, in Cambridge, Massachusetts.
  • Chernew ME; Michael E. Chernew is the Leonard D. Schaeffer Professor of Health Care Policy and director of the Healthcare Markets and Regulation (HMR) Lab in the Department of Health Care Policy, Harvard Medical School, in Boston, Massachusetts.
  • Fendrick AM; A. Mark Fendrick is a professor in the Department of Internal Medicine and director of the Center for Value-Based Insurance Design at the University of Michigan, in Ann Arbor, Michigan.
  • Cutler DM; David M. Cutler is the Otto Eckstein Professor of Applied Economics in the Department of Economics at Harvard University and a research associate at the National Bureau of Economic Research, in Cambridge, Massachusetts.
Health Aff (Millwood) ; 39(9): 1546-1556, 2020 09.
Article em En | MEDLINE | ID: mdl-32897792
ABSTRACT
Life expectancy in the US increased 3.3 years between 1990 and 2015, but the drivers of this increase are not well understood. We used vital statistics data and cause-deletion analysis to identify the conditions most responsible for changing life expectancy and quantified how public health, pharmaceuticals, other (nonpharmaceutical) medical care, and other/unknown factors contributed to the improvement. We found that twelve conditions most responsible for changing life expectancy explained 2.9 years of net improvement (85 percent of the total). Ischemic heart disease was the largest positive contributor to life expectancy, and accidental poisoning or drug overdose was the largest negative contributor. Forty-four percent of improved life expectancy was attributable to public health, 35 percent was attributable to pharmaceuticals, 13 percent was attributable to other medical care, and -7 percent was attributable to other/unknown factors. Our findings emphasize the crucial role of public health advances, as well as pharmaceutical innovation, in explaining improving life expectancy.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Preparações Farmacêuticas / Expectativa de Vida Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Health Aff (Millwood) Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Preparações Farmacêuticas / Expectativa de Vida Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Health Aff (Millwood) Ano de publicação: 2020 Tipo de documento: Article